Who Owns Vericel Company?

Who Owns Vericel Corporation?

Understanding Vericel Corporation's ownership is key to grasping its strategic path and accountability. A significant shift occurred in 2014 when Aastrom Biosciences, Inc. acquired Genzyme Corporation's cell therapy unit, leading to the rebranding as Vericel Corporation.

This acquisition transformed the company into a commercial entity with established products, moving beyond its development-stage origins.

Vericel Corporation, originally Aastrom Biosciences, Inc., is a publicly traded biopharmaceutical company focused on advanced cell therapies. As of August 2025, its market capitalization stands at approximately $1.79 billion USD, with 50.5 million shares outstanding as of July 31, 2025. The ownership is largely institutional, complemented by insider and public investor stakes. The company's product portfolio includes treatments for sports medicine and severe burn care, such as Vericel BCG Matrix.

Vericel Corporation's origins trace back to Aastrom Biosciences, Inc., founded in 1989 with a focus on developing patient-specific cellular therapies. While specific founder details and initial ownership percentages are not widely publicized, the company's early operations were based in Ann Arbor, Michigan. The transformation into Vericel marked a significant shift in its ownership structure and commercialization strategy.

Founding Entity

Vericel's foundational roots are in Aastrom Biosciences, Inc., established in 1989. This entity initially concentrated on pioneering expanded cellular therapy technologies.

Early Focus

The early mission of Aastrom Biosciences was centered on the development of patient-specific expanded cellular therapies. This laid the groundwork for future advancements in regenerative medicine.

Key Acquisition

A pivotal moment occurred in 2014 when Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business. This acquisition significantly broadened its product portfolio and market presence.

Name Change and Relocation

Following the acquisition, Aastrom Bio officially rebranded as Vericel Corporation in October 2014. The company also relocated its headquarters to Cambridge, Massachusetts.

Commercialization Milestone

The acquisition transformed Vericel into a commercial-stage company, integrating revenue-generating products like Epicel and Carticel. This marked a significant step from its prior development-stage status.

Integration of Expertise

The acquired business unit from Sanofi brought experienced personnel in cell therapies, complementing the existing leadership from Aastrom Biosciences. This integration was crucial for the company's new direction.

The transition from Aastrom Biosciences to Vericel Corporation in 2014 was a transformative event, driven by the acquisition of Sanofi's cell therapy division. This strategic move not only expanded Vericel's commercial offerings with products like Epicel and Carticel but also shifted its operational base to Cambridge, Massachusetts. While the specific founding individuals of Aastrom Biosciences and their initial equity stakes are not detailed, the leadership team that oversaw this acquisition and rebranding effectively became the early management of Vericel. The financial details of the acquisition itself, including the undisclosed amount paid to Sanofi, represent a key aspect of the company's early financial structure and ownership evolution. Understanding this period is crucial for grasping the current Vericel ownership landscape and its trajectory. For a deeper dive into the competitive environment, explore the Competitors Landscape of Vericel.

Vericel's Early Ownership Evolution

Vericel Corporation's ownership structure is a result of a significant acquisition and rebranding event in 2014. The company's journey began as Aastrom Biosciences, Inc., a developer of cellular therapies.

• Aastrom Biosciences, Inc. was founded in 1989.
• The company's initial focus was on patient-specific expanded cellular therapies.
• In 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business.
• This acquisition led to the rebranding of Aastrom Bio as Vericel Corporation in October 2014.
• The company's headquarters moved to Cambridge, Massachusetts, following the acquisition.
• The acquired business unit brought established products and commercial expertise.

Complete Vericel Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Vericel Corporation's ownership landscape has transformed significantly since its initial public offering in 1997. As a NASDAQ-listed entity (VCEL), its shareholder base now comprises a diverse mix of institutional investors, mutual funds, ETFs, company insiders, and the general public.

As of July 22, 2025, Vericel Corporation is held by 648 institutional owners and shareholders, collectively managing 73,602,590 shares. This substantial institutional backing, representing approximately 63.53% of the company's stock, indicates a strong reliance on these entities for governance and strategic direction. Among the leading institutional stakeholders are BlackRock, Inc., holding 15.86% (7,982,151 shares), and Vanguard Group Inc., with 6.94% (3,493,510 shares). Other significant institutional investors include iShares Core S&P Small-Cap ETF, Brown Capital Management Llc, State Street Corp, Fmr Llc, Invesco Ltd., Conestoga Capital Advisors, LLC, and Congress Asset Management Co /ma.

Vericel's Ownership Dynamics

Vericel's ownership structure reflects its status as a publicly traded company. Institutional investors play a dominant role, influencing the company's trajectory. Understanding these major shareholders is key to grasping who controls Vericel stock.

• Institutional investors own over 63% of Vericel's stock.
• BlackRock, Inc. is the largest single shareholder.
• Insider ownership is relatively small, around 1.06%.
• The company's stock ownership breakdown shows significant public float.
• Vericel Corporation is a public company, not privately held.

Insider ownership, representing those within Vericel's management and board, accounts for approximately 1.06% of the company's shares, though some data points to a higher figure of up to 7.20%. The remaining 35.41% is distributed among public companies and individual investors. A notable event influencing ownership was the May 2018 public offering, which raised approximately $74.8 million in gross proceeds. These funds were earmarked for general corporate purposes and strategic growth initiatives, including potential acquisitions or in-licensing opportunities, as detailed in the Growth Strategy of Vericel. This offering, along with other capital-raising activities, has contributed to the ongoing evolution of Vericel's shareholder base and its overall financial ownership structure.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Board of Directors at Vericel Corporation is responsible for the company's strategic direction and oversight. This group of experienced individuals, with an average tenure of 12.4 years, guides the executive leadership team. Their collective expertise spans biotechnology, finance, and operational management, ensuring robust governance.

Vericel's voting structure is based on a straightforward one-share-one-vote principle for its common stock. As of April 30, 2025, there were 50,135,864 shares of common stock outstanding and eligible to vote. Director candidates require a plurality of the votes cast at the Annual Meeting for election. Importantly, shares held as Restricted Stock Units (RSUs) do not carry voting rights until they vest and are converted into common stock. The company actively engages with its shareholders, participating in investor conferences and meetings throughout 2024 to discuss performance, strategy, and compensation, reflecting a commitment to transparency and shareholder relations. Understanding the Marketing Strategy of Vericel can provide further context on how the company aims to grow and create value for its stakeholders.

Vericel's Shareholder Structure and Voting Rights

Vericel operates with a standard voting system, where each share of common stock grants one vote. This ensures that Vericel ownership is directly tied to voting power.

• One-share-one-vote system for common stock.
• 50,135,864 shares outstanding as of April 30, 2025.
• RSUs do not have voting rights until vested.
• No evidence of dual-class shares or special voting rights.
• Active shareholder engagement through conferences and meetings.

Vericel Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Vericel Corporation has seen shifts in its ownership landscape over the past few years, with institutional investors maintaining a significant presence. As of July 22, 2025, these entities collectively held over 73 million shares, indicating continued confidence in the company's trajectory. This period also witnessed strategic adjustments by some major institutional players, reflecting dynamic market engagement.

Recent developments at Vericel Corporation highlight advancements in its cell therapy portfolio and a positive financial outlook. The company's focus on innovation has led to key regulatory approvals, enhancing its market position. These strategic moves are supported by a generally optimistic analyst consensus, positioning Vericel for continued growth.

Product Advancements

The FDA approved an sBLA for MACI Arthro in August 2024, expanding its commercial availability. Vericel also received FDA approval for NexoBrid in 2023, with a supplemental filing for pediatric use under consideration.

Financial Performance and Outlook

Total revenues reached approximately $210.4 million in 2023, with projected growth of 20% to 23% for 2025. The company anticipates a gross margin of 74% and an adjusted EBITDA margin of 26% for 2025.

Insider and Institutional Activity

Insider selling occurred in late 2024 and early 2025, with executives and directors selling shares totaling over $11.5 million. Institutional investors continue to be major shareholders, with some actively increasing their stakes.

Market Sentiment

As of July 2025, analysts maintain a 'Moderate Buy' rating on Vericel stock. This sentiment reflects optimism regarding the company's innovative products and its strategic market positioning, aligning with its Mission, Vision & Core Values of Vericel.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE